In addition to VIP236, Vincerx’s pipeline has a clinical-stage cyclin-dependent kinase-9 (CDK9) inhibitor program, VIP152 2, and two preclinical ADC candidates that exemplify the differentiated ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer. In part 2 of ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the ...

Antibody–drug conjugates (ADCs) deliver potent anti-cancer drugs directly to tumor cells by taking advantage of the ability of antibodies to recognize cancer cell receptors. This targeted ...